Full Press Release Details
Patients with grade 4 gliomas, particularly those experiencing recurrence, need better treatment options. Researchers are developing NEO100, a clinical-grade version of perillyl alcohol, a natural compound, to be delivered intranasally (IN) as a potential cancer therapy.
In this study, a 40-year-old woman with a grade 4 astrocytoma underwent standard surgery and chemotherapy but experienced tumor recurrence after six cycles of treatment. She then began daily IN NEO100 therapy using a nebulizer and nasal mask. Over 13 months, MRI scans showed continuous tumor regression until the tumor became barely visible. She had no serious side effects, and her quality of life improved significantly.
This case suggests that IN NEO100 therapy is a promising, well-tolerated treatment for recurrent glioma, demonstrating significant tumor reduction and potential for broader clinical use.
Read The Paper
Patient with recurrent grade 4 astrocytoma responding favorably to intranasal delivery of NEO100, highly pure perillyl alcohol: illustrative case.
Authors: Axel H. Schönthal, PhD 1 , Stephen Swenson, PhD 2 , Frank M. Senecal, MD 4 , Rhonda Mittenzwei, MD 4,5 , John L. Go, MD 6 , and Thomas C. Chen, MD, PhD 2,7,8
1 Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California 2 Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California 3 Department of Hematology and Oncology, Northwest Medical Specialties, Tacoma, Washington 4 King County Medical Examiner’s Office, Department of Public Health, Seattle, Washington 5 Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington 6 Neuroradiology Division, David Geffen School of Medicine, University of California, Los Angeles, California 7 NeOnc Technologies, Inc., Westlake Village, California 8 USC/Norris Comprehensive Cancer Center, Los Angeles, California